Johnson & Johnson $JNJ Stock Sold by Palisade Asset Management LLC

Key Points

• Palisade Asset Management cut its Johnson & Johnson stake by 4.1%, selling 4,110 shares, but still held 96,762 shares valued at about $25.6 million at quarter-end.
• Johnson & Johnson beat quarterly earnings expectations, reporting $2.59 per share and $25.40 billion in revenue; revenue grew 5.9% year over year, and the company reaffirmed 2026 EPS guidance of $11.05–$11.15.
• Analysts maintain a Moderate Buy consensus rating, with an average price target of $275.92.

Palisade Asset Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 96,762 shares of the company's stock after selling 4,110 shares during the quarter. Johnson & Johnson makes up about 2.4% of Palisade Asset Management LLC's portfolio, making the stock its 7th biggest holding. Palisade Asset Management LLC's holdings in Johnson & Johnson were worth $25,617,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in JNJ. CKW Financial Group increased its stake in shares of Johnson & Johnson by 0.9% during the third quarter. CKW Financial Group now owns 4,269 shares of the company's stock worth $1,104,000 after purchasing an additional 37 shares in the last quarter. Silver Coast Investments LLC raised its position in shares of Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after purchasing an additional 39 shares during the last quarter. Townsend Asset Management Corp NC ADV raised its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock worth $1,630,000 after purchasing an additional 39 shares during the last quarter. Triumph Capital Management lifted its stake in Johnson & Johnson by 1.6% in the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after buying an additional 39 shares in the last quarter. Finally, Kwmg LLC lifted its stake in Johnson & Johnson by 1.7% in the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company's stock valued at $631,000 after buying an additional 39 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have commented on JNJ. Wall Street Zen lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Weiss Ratings downgraded Johnson & Johnson from a "buy (b+)" rating to a "buy (b-)" rating in a research report on Friday, October 23rd. Royal Bank Of Canada dropped their price target on Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating for the company in a research report on Wednesday, October 14th. TD Cowen reiterated a "buy" rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $275.92.

Insider Activity

In other news, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares of the company's stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 1.4%

NYSE JNJ opened at $276.14 on Friday. Johnson & Johnson has a 52 week low of $185.12 and a 52 week high of $282.02. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The business's fifty day simple moving average is $265.91 and its 200-day simple moving average is $248.30. The firm has a market cap of $664.76 billion, a PE ratio of 41.84, a P/E/G ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion for the quarter, compared to analysts' expectations of $25.38 billion. During the same quarter in the previous year, the company posted $2.80 EPS. The company's revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson's payout ratio is 81.21%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.